Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, et al. SEER Cancer Statistics Review. 1975–2016. https://seer.cancer.gov/csr/1975_2016/. Accessed 7 Nov 2021.
Fermé C, Eghbali H, Meerwaldt JH, et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin’s disease. N Engl J Med. 2007;357:1916–27.
Article
Google Scholar
Engert A, Plütschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N Engl J Med. 2010;363:640–52.
Article
CAS
Google Scholar
Connors JM. State-of-the-art therapeutics: Hodgkin´s lymphoma. J Clin Oncol. 2005;23:6400–8.
Article
CAS
Google Scholar
Engert A, Horning S, editors. Hodgkin Lymphoma. Heidelberg: Springer; 2011.
Google Scholar
Fuchs M, Goergen H, Kobe C, et al. Positron emission tomography-guided treatment in early-stage favorable Hodgkin Lymphoma: final results of the international, radomized phase II HD16 trial by the German Hodgkin Study Group. J Clin Oncol. 2019;37(31):2835–45.
Article
CAS
Google Scholar
Eichenauer DA, André M, Johnson P, et al. Controversies in the treatment of classical Hodgkin Lymphoma. Hemasphere. 2008;2(5):e149.
Article
Google Scholar
Engert A, Younges A (eds): Principles of radiation therapy for Hodgkin Lymphoma in Hodgkin Lymphoma: a comprehensive overview. Basel: Springer International Publishing; 2015. p. 157–77.
Kobe C, Dietlein M, Franklin J, et al. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced stage Hodgkin lymphoma. Blood. 2008;112:3989–94.
Article
CAS
Google Scholar
Weihrauch MR, Re D, Bischoff S, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin´s disease. Ann Hematol. 2002;81:20–5.
Article
CAS
Google Scholar
Gallamini A, Rigacci L, Merli F, et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin´s disease. Haematologica. 2006;91:475–81.
PubMed
Google Scholar
Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin´s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol. 2007;25:3746–52.
Article
CAS
Google Scholar
Engert A, Haverkamp H, Kobe C, et al. Reduced-intensity chemotherapy and-guided radiptheray in patients with advanced stage Hodgkin´s lymphoma (HD15 trial): a randomized, open label phase 3 non-inferiority trial. Lancet. 2012;379:1791–9.
Article
CAS
Google Scholar
Borchmann P, Goergen H, Kobe C, et al. PET-guided treatment in patients with advanced-stage Hodgkin´s lymphoma (HD18): final results of an open-label, international, randomized phase 3 trial by the German Hodgkin Study Group. Lancet. 2017;390:2790–802.
Article
Google Scholar
Borchman P, Plütschow A, Kobe C, et al. PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicenter, open-label, randomized, phase 3 trial. Lancet Oncol. 2021;22(2):223–34.
Article
Google Scholar
Raemaekers JMM, André MPE, Federico M, et al. Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relaps: clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 Trial. J Clin Oncol. 2014;32(12):1188–94.
Article
Google Scholar
Radford J, Illidge T, Counsell N, et al. Results of trial of PET-directed therapy for early-stage Hodgkin´s lymphoma. N Engl J Med. 2015;372:1598–607.
Article
CAS
Google Scholar
Meignan M, Cottereau AS, Versari A, et al. Baseline metabolic tumor volume predicts outcome in high-tumor-burden follicular lymphoma: apooled analysis of three multicentre studies. J Clin Oncol. 2016;34:3618–26.
Article
Google Scholar
Gallamini A, Barrington SF, Biggi A, et al. The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five point scale. Haematologica. 2014;99:1107–13.
Article
Google Scholar
Akhtari M, Milgrom SA, Pinnix CC, et al. Reclassifying patients with early-stage Hodgkin lymphoma based on functional radiographic markers at presentation. Blood. 2018;131:84–94.
Article
CAS
Google Scholar
Kanoun S, Rossi C, Berriolo-Riedinger A, et al. Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging. 2014;41:1735–43.
Article
Google Scholar
Cottereau AS, Versari A, Loft A, et al. Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial. Blood. 2018;131:1456–63.
Article
CAS
Google Scholar
Song MK, Chung JS, Lee JJ, et al. Metabolic tumor volume by positron emission tomography/computed tomography as a clinical parameter to determine therapeutic modality for early stage Hodgkin’s lymphoma. Cancer Sci. 2013;104:1656–61.
Article
CAS
Google Scholar
Moskowitz AJ, Schoder H, Gavane S, et al. Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma. Leuk Lymphoma. 2009;50:1257–60.
Article
Google Scholar
Mettler J, Müller H, Voltin CA, et al. Metabolic tumor volume for response prediction in advance-stage Hodgkin Lymphoma. J Nucl Med. 2019;60:207–11.
Article
CAS
Google Scholar
Kim TM, Paeng JC, Chun IK, et al. Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the international prognostic index for patients with diffus lage B Cell lymphoma. Cancer. 2013;119(6):1195–202.
Article
CAS
Google Scholar
Meignan M, Sasanelli M, Casasnovas RO, et al. Metabolic tumour volumes measured at staging in lymphoma: Methodological evaluation on phantom experiments and patients. Eur J Nucl Med Mol Imaging. 2014;41:1113–22.
Article
CAS
Google Scholar
Carlier T, Bailly C. State-of-theart and recent advances in quantification for therapeutic follow-up in oncology using PET. Front Med. 2015;2:18.
Article
Google Scholar
Tutino F, Puccini G, Linguanti F, et al. Baseline metabolic tumor volume calculation using different SUV thresholding methods in Hodgkin Lymphoma patients: interobserver argreement and reproducibility across software platforms. Nuc Med Com. 2021;42(3):284–91.
Article
CAS
Google Scholar
Borchmann S. Liquid biopsy in Hodgkin lymphoma – moving beyond the proof of principle. Br J Haematol. 2021;195(4):493–4.
Article
Google Scholar